| |
|
David Kauffmann
David Kauffmann has been Chairman of CMC since 2002. He is a founding general partner of EEP, a € 80 million private equity fund investing in the Life Sciences and IT / Communication Industries. At EEP, David focuses on investing in life science growth companies. Prior to EEP David was Principal at CAI, a New York based Private Equity firm, where he also focused on investing in life science services companies. He is the former chairman of Aster Cephac SA, a leading CRO specializing in Clinical trials and Bioanalysis now part of the SGS Group, and a former investment manager of BioResearch Inc a leading North American Preclinical company acquired by Charles River Inc.. He holds an MBA from IMD in Lausanne, Switzerland.
Thomas Balland
Thomas Balland is an investment director at Innoven Partenaires, a Paris-based venture capital fund. He specializes in software, wireless and medical devices investments. Thomas has been a director of CMC Biologics since 2004 and also serves on the boards of Monte Cristo, Navx, SpineGuard, SpineVision and Traqueur (Alternext: ALTRA). Previously, Thomas was on the Board of Innoven portfolio company gate5 AG, which was sold to Nokia in 2006 and he was investment manager for Digiplug SA, sold to Faith (Tokyo: 4295). Thomas has more than 8 years of venture capital investment experience. Prior to joining Innoven in 2002, he held various positions with Mars Inc., Up&Up and Vivendi. Thomas has dual degrees in engineering and finance from INSA Lyon and ESCP-EAP, respectively.
Claes Glassell
Claes Glassell joined the CMC board of directors in 2005. Claes is President & CEO of Cerus Corporation Inc. He is the former President of Cambrex Corporation Inc. and has formerly held senior positions with Akzo Nobel NV, Nobel Industries AB and Berol Kemi AB. His areas of expertise includes 20 years of executive positions in publicly listed Life Sciences companies responsible for bioprocessing, active ingredients business, registered therapeutic agents and various support services.
Bill Henry
Bill Henry has been a Board Director of CMC since 2005. He is an investment Partner at Celtic Pharma with particular responsibility for the manufacturing aspects of investments. Formerly, he has held a number of senior executive positions in biologics manufacturing including: Head of manufacturing at PowderMed, a successful DNA vaccine and devise company which was acquired by Pfizer in 2006; and Head of UCB Celltech Global Manufacturing. Bill began his career as a research scholar for British Petroleum and gained a PhD in chemistry from the University of Edinburgh. With an original background in biochemistry, he joined Zeneca's emerging Bioproducts business to commission a large mycoprotein manufacturing capability before moving on to become the European Operations Director for the veterinary pharmaceutical business that was eventually acquired by Schering Plough.
Peter S. Laino
Peter S. Laino is a Managing Partner of Monitor Clipper Partners. He joined MCP in August 1998. Previously, Mr. Laino was Director, Development for K-III Communications Corporation, a media holding company formed by Kohlberg Kravis Roberts & Co., L.P. Earlier, he was an associate in the corporate finance group of Dillon, Read & Co., Inc., and before that, he was a principal of Riverside Partners, a small Monitor-sponsored private equity fund, and prior to that he was a consultant at Monitor. Mr. Laino received a B.A., cum laude, in English from Williams College, and an M.B.A. from The Harvard Graduate School of Business Administration.
Steve Lehman
Steve Lehman, Principal at Monitor Clipper Partners (MCP), joined CMC's Board of Directors in 2008. Based out of MCP's Zurich office, Mr. Lehman develops and manages growth equity and leveraged buyout investments throughout Europe. After several years working at MCP's strategy consulting affiliate Monitor Company Group, Mr. Lehman joined MCP in 2003. Mr. Lehman received a B.A., magna cum laude, in economics and mathematics from Williams College in Massachusetts. He also sits on the Board of Microgame S.p.A., an Italy-based gaming technology company.
William L. Young
William L. Young is a Founder and Managing Partner of MCP. Mr. Young has worked with Monitor since 1989 and joined the firm in 1995 as a Group Managing Director. Prior to joining Monitor, Mr. Young was a founding partner of Westbourne Management Group in Toronto, Canada, providing management services to companies requiring or undertaking significant restructurings or turnarounds. From 1981 to 1989, Mr. Young was a strategy consultant at Bain and Company in London, England, where he was elected to the partnership in 1985. Mr. Young is a certified professional engineer and was previously employed as a design engineer by Imperial Oil, Exxon’s Canadian affiliate.
Mr. Young received his Bachelor’s degree with Honors from Queen’s University in Kingston, Ontario and an M.B.A. with Distinction from the Harvard Graduate School of Business Administration. Mr. Young is currently on the Board of Queen’s University in Kingston, Ontario and the Belmont Day School and has served as Director of Codere, Hinckley and Technal.
|
|
